Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Summary The White House has announced “most-favored-nation” pricing agreements with 26 pharmaceutical companies over the past year. The stated goal is to bring US drug prices closer to prices paid
Why this document exists A medicine can be approved by regulators and still fail commercially, because the public bodies and insurers who pay for medicines apply their own, separate test.
Summary Tennessee enacted the FAIR Rx Act, banning pharmacy benefit manager-owned pharmacies from operating in the state. Express Scripts and the PCMA filed separate lawsuits in June 2026 to block
Summary A proposed CMS rule would close a formulation-switch loophole in Medicare’s drug price negotiation program. Merck’s Keytruda QLEX and Bristol Myers Squibb’s Opdivo Qvantig — subcutaneous versions of established
On 9 June 2026, the European Commission published the first Joint Clinical Assessment (JCA) under the EU HTA Regulation. The drug assessed was tovorafenib (Ojemda), an oral RAF inhibitor for
Summary The U.S. and U.K. have reached a trade deal that will exempt drugs imported from the U.K. from tariffs for three years in exchange for pricing concessions. This agreement
Conclusions & Strategic Implications What great looks like; near-term moves for R&D and access teams; mid-term capabilities roadmap. Appendices Glossary (HTA, QALY, ICER, BIA, IRP, MEA, VPAG, etc.) Abbreviated methodological
Operating Model, Governance & Ways of Working End-to-end market access strategy frame: What is the winning ambition? Where to play? How to win? How to execute? (decision gates, RASIC, KPIs).
Economic evaluation 101 Economic evaluation compares alternative health interventions by examining both their costs and their consequences, enabling decision-makers to allocate resources efficiently. In health care, this is a structured,
Understanding how different markets and product types shape pricing, reimbursement, and access strategies. Global Market Access Models (Short “How It Works” Overviews) United States Europe / HTA-driven systems (conceptual) Japan